Tcr2 Therapeutics Inc
TCRR
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.11M
Close$
$9.43
537.3% upside
Current Fair Value
537.3% upsideUndervalued by 537.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $58.11 Million |
|---|---|
| Enterprise Value | $49.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.93 |
| Beta | 1.93 |
| Outstanding Shares | 39,220,984 |
Return
| Return on Equity | -160.96% |
|---|---|
| Return on Assets | -107.65% |
| Return on Invested Capital | -159.36% |
Valuation & Multiples
| P/E Ratio | -0.38 |
|---|---|
| PEG | -0.97 |
| Price to Sales | - |
| Price to Book Ratio | 0.74 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.3 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tcr2 Therapeutics Inc
118 employees
CEO: Garry Menzel TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Const...